Virological response of chronic hepatitis C treated with peg-interferon α-2a and Ribavirin

Jiang XueQiang; Zou XiaoJing; Tian DeYing

Issue 4

Apr. 2011

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2011 > 27(4): 417-419

PDF( 2572 KB)

Virological response of chronic hepatitis C treated with peg-interferon α-2a and Ribavirin

Research funding:

Published Date: 2011-04-20

Abstract

Abstract

Objective To evaluate the management of chronic hepatitis C with PEG-IFNα-2a and ribavirin.Methods We retrospectively analyzed the virological response of 58 patients with different genotypes of hepatitis C virus (HCV) after anti-HCV management.Among them, 43 cases experienced HCV genotype 1 infection, and 15 cases were infected with genotype 2.All the Patients were assigned for PEG-IFN α-2a combined ribavirin for 48 weeks, HCV RNA was tested before treatment, 12 and 24 weeks post management, at the end of treatment, 24 and 48 weeks after treatment was terminated.Results The rapid virological responses of the genotype 1 patients was 48.8%, obviously lower than the genotype 2 (80%, P<0.05) .After 48 weeks of termination of treatment, there were significant deviation of 53.5, and 86.7% (P<0.05) , respectively between the two genotypes.The rapid virological responses for the patients with high viral load and lower viral load were about 46.2% and 93.8% (P<0.05) , respectively.Obvious deviation was observed between them at the point of 48 weeks after treatment termination, they were 51.3% and 84.2% (P<0.05) .Conclusion PEG-IFNα-2a in combination with ribavirin can effectively treat patients with different genotypes of HCV.The efficacy is better for genotype 2 than 1, and patients with low viral load than high viral load.
- hepatitis C,
- chronic,
- interferon alfa-2a

FullText(HTML)

References(11)

References

[1]Wang YS, Youngster S, Bausch J, et al.Identification of themajor positional isomer of pegylated interferon alpha-2b[J].Bioehemistry, 2000, 39 (35) :10634-10640.

[2]Ghany MG, Strader DB, Thomas DL, et al.Diagnosis, management, and treatment of hepatitis C:all update[J].Hepatology, 2009, 49 (4) :1335-1374.

[3]McCanghan GW, Omata M, Amarapurkar D, et al.Asian PacificAssociation for the Study of the Liver consensus statements onthe diagnosis, management and treatment of hepatitis C virusinfection[J].J Gastroenterol Hepatol, 2007, 22 (5) :615-633.

[4]中华医学会.丙型肝炎防治指南[J].中华传染病杂志, 2004, 22 (2) :131-136.

[5]Savino B, Mitchell LS, Stuart KR, et al.Efficacy and Safetyof Peginterferon Alfa-2a (40KD) Plus Ribavirin in HepatitisC Patients with Advanced Fibrosis and Cirrhosis[J].Hepatology, 2010, 51 (2) :388-397.

[6]Dixit NM, Perelson AS.The metabolism, pharmacokinetics andmechanisms of antiviral activity of ribavirin against hepatitis Cvirus[J].Cell Mol Life Sci, 2006, 63 (7-8) :832-842.

[7]Fried MW, Shiffman ML, Reddy KR, et al.Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection[J].NEngl J Med, 2002, 347 (13) :975-982.

[8]Dongliang G, Jacques F, Alexander J, et al.Genetic variationin IL28B predicts hepatitis C treatment-induced viralclearance[J].Nature, 2009, 461:399-401.

[9]于建武, 孙丽杰, 李晓光, 等.快速和早期病毒学应答对慢性丙型肝炎患者持续病毒学应答的预测价值[J].中华传染病杂志, 2008, 26 (1) :36-39.

[10]Fried MW, Hadziyannis SJ, Shiffman M, et al.Rapid virological response is a more important predictor of sustainedvirological response (SVR) than genotype in patients withchronic hepatitis C virus infection[J].Hepatology, 2008, 48 (Suppl 2) :S5.

[11]Foster GR, Fried MW, Hadziyannis SJ, et al.Prediction ofsustained virological response in chronic hepatitis C patientstreated with peginterferon alfa-2a (40KD) and ribavirin[J].Scand J Gastroentero, 2007, 42 (2) :247-255.

Relative Articles

[1]	Xu JinFeng, Zhang XiaoHui, Liu YaLi, Zhang Jing. Influencing factors for hemolytic anemia in patients with chronic hepatitis C treated by ribavirin combined with pegylated interferon-α[J]. Journal of Clinical Hepatology, 2019, 35(2): 319-322. doi: 10.3969/j.issn.1001-5256.2019.02.015
[2]	Yang CaiXia. Immune tolerance after drug withdrawal in a patient with chronic hepatitis B receiving PEG- IFNα- 2a treatment[J]. Journal of Clinical Hepatology, 2017, 33(1): 160-162. doi: 10.3969/j.issn.1001-5256.2017.01.035
[3]	Wu XiaoLi. Influence of combination mode of PEG-IFNα-2a and adefovir dipivoxil on outcome of patients with HBeAg-positive chronic hepatitis B[J]. Journal of Clinical Hepatology, 2017, 33(12): 2311-2315. doi: 10.3969/j.issn.1001-5256.2017.12.011
[4]	Zhang Yu, Cao Ying, Zhang RenWen, Zhang XiaXia, Lu HaiYing, Wu ChiHong, Huo Na, Yu Min, Liu Dan, Xu XiaoYuan. Natural resistance mutations to direct- acting antiviral agents in interferon / ribavirin treatment- experienced and treatment- nave patients with chronic hepatitis C in Beijing,China[J]. Journal of Clinical Hepatology, 2016, 32(4): 711-715. doi: 10.3969/j.issn.1001-5256.2016.04.020
[5]	Chen XiaoYun, Zheng YanHong, Jin Yi, Yu HaiBin, Ma LiNa, Chen XinYue. Correlation between routine blood test results and antiviral effect in patients with refractory chronic hepatitis C treated with pegylated interferon-α[J]. Journal of Clinical Hepatology, 2016, 32(7): 1319-1322. doi: 10.3969/j.issn.1001-5256.2016.07.021
[6]	Yang Long, Yang Yang, Jiang XueHua, Chen ZhiYong. Efficacy of peginterferon α- 2a in treatment of chronic hepatitis B resistant to multiple nucleos( t) ide analogues[J]. Journal of Clinical Hepatology, 2016, 32(4): 691-694. doi: 10.3969/j.issn.1001-5256.2016.04.016
[7]	Peng MeiJuan, Wang Wei, Yang XiaoFei, Hao ChunQiu, Bai XueFan, Jia ZhanSheng, Lian JianQi, Zhang Ye. Influence of pegylated interferonα- 2a versus telbivudine on renal function in patients with chronic hepatitis B[J]. Journal of Clinical Hepatology, 2016, 32(4): 682-686. doi: 10.3969/j.issn.1001-5256.2016.04.014
[8]	Sun JianMin. Efficacy of low-dose interferon α-1b combined with ribavirin and thymosin α1 versus standard treatment for chronic hepatitis C: a comparative study [J]. Journal of Clinical Hepatology, 2015, 31(1): 107-109. doi: 10.3969/j.issn.1001-5256.2015.01.023
[9]	Liu YunHua, Li Zhen, Liu Li, Peng Dan, Li WeiKun, Chang LiXian, Jia Ting, Yang YongRui, Li HuiMin, Wang LiQian. Clinical study of pegylated interferon α-2a in treatment of children with HBe Ag-positive chronic hepatitis B[J]. Journal of Clinical Hepatology, 2015, 31(2): 193-197. doi: 10.3969/j.issn.1001-5256.2015.02.012
[10]	Liu ZhiHua, He HaiTang, Hu Jing, Fu QunXiang, Luo KangXian. Efficacy of pegylated interferon α-2a in HBe Ag-negative chronic hepatitis B patients and its influencing factors[J]. Journal of Clinical Hepatology, 2015, 31(5): 697-701. doi: 10.3969/j.issn.1001-5256.2015.05.016
[11]	Lin Wei, Si JianLin, Zhang Jian, Maimaitijiang·Wubuliaishan, Hu ZhiMing, Li DongZeng, Geng Nan. Pegylated interferon alpha-2a combined with ribavirin for chronic hepatitis C: a clinical analysis of 160 patients of Uygur nationality or Han nationality[J]. Journal of Clinical Hepatology, 2015, 31(11): 1831-1836. doi: 10.3969/j.issn.1001-5256.2015.11.015
[12]	Cai ShaoPing, Zhang WenJin, He WeiPing, Fan ZhenPing, Ji YingJie. Efficacy and safety of interferon plus ribavirin in elderly patients with chronic hepatitis C: report of 4 cases[J]. Journal of Clinical Hepatology, 2014, 30(1): 69-71. doi: 10.3969/j.issn.1001-5256.2014.01.019
[13]	Lu JianGuo. Effect of pegylated interferon α-2a combined with thymosin α1 on quality of life in patients with chronic hepatitis B[J]. Journal of Clinical Hepatology, 2013, 29(12): 922-925. doi: 10.3969/j.issn.1001-5256.2013.12.012
[14]	Zhao XiaoLing, Zhang YongGang. Clinical efficacy of ribavirin combined with different doses of interferon α- 2b in patients with chronic hepatitis C genotypes 2 and 3[J]. Journal of Clinical Hepatology, 2013, 29(10): 780-783. doi: 10.3969/j.issn.1001-5256.2013.10.014
[15]	Zhang SuMei, Xie YuMei, Zhang Ying, Guo YongHong, Wei Xin, Jiang Na, Zhou Yun, Jia ZhanSheng. Potential of G-CSF supplementation to counter the neutrophil effects of standard PEG-IFNα plus ribavirin combination therapy for treating HCV-related cirrhosis [J]. Journal of Clinical Hepatology, 2013, 29(5): 348-351.
[16]	Hao KunYan, He ZhangLun, Yu LeCheng, Sheng YunFeng, Wang MaoRong. Rhabdomyolysis during the antiviral therapy against chronic hepatitis C with the combination of interferon and ribavirin:a case report[J]. Journal of Clinical Hepatology, 2011, 27(6): 654-655.
[17]	Zhu HaiJuan, Li YongHong, Guo LiPing. One case report of hysteria in a HCV patient being treated with PEG-IFN α-2a[J]. Journal of Clinical Hepatology, 2011, 27(6): 656-657.
[18]	Wei Xin, Xie YuMei, Chen Lin, Pan Lei, Hao ChunQiu, Wang JiuPing, Bai XueFan, Jia ZhanSheng. Antiviral therapy with pegylated interferon alpha-2a plus ribavirin in patients with HCV related cirrhosis and to establish the grading for standard therapy[J]. Journal of Clinical Hepatology, 2011, 27(1): 89-92.
[19]	Zhu Yan, Mao Qing, Zhang ZhangJiang, Sun Wei, Hu YaJun, Tan ChaoXia, Wang XiaoHong. Retreatment with pegylated interferon alpha-2a/2b and ribavirin in previous relapsers with chronic hepatitis C[J]. Journal of Clinical Hepatology, 2011, 27(1): 86-88.
[20]	Zheng YingYing, Fan XiaoHong, Wang LiFen, Tian Di, Huo Na, Lu HaiYing, Wu ChiHong, Xu XiaoYuan, Wei Lai. Efficacy and side effects of PEG-IFNα-2a plus ribavirin on elderly patients with chronic hepatitis C[J]. Journal of Clinical Hepatology, 2011, 27(8): 821-823.

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (3600) PDF downloads(1001)

Virological response of chronic hepatitis C treated with peg-interferon α-2a and Ribavirin

Abstract

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Virological response of chronic hepatitis C treated with peg-interferon α-2a and Ribavirin

Abstract

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content